KLOW Blend 80mg – PharmaTech

KLOW Blend is a multi-peptide research formulation combining GHK-Cu, BPC-157, TB-500, and KPV into a single lyophilized preparation.

The PharmaTech formulation contains 80 mg of total peptide material, composed of GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, and KPV 10mg.

The four components represent distinct areas of peptide research, including extracellular matrix biology, cellular migration, tissue remodeling, inflammatory signaling, cytoskeletal dynamics, and cellular recovery pathways.

The scientific rationale for KLOW is based primarily on the complementary biological characteristics of its individual components. Research on the complete four-peptide combination remains limited compared with the substantially larger body of component-level research.

OVERVIEW

KLOW Blend is a multi-peptide research formulation combining GHK-Cu, BPC-157, TB-500, and KPV into a single lyophilized preparation.

The PharmaTech formulation contains 80 mg of total peptide material, composed of:

  • GHK-Cu — 50 mg
  • BPC-157 — 10 mg
  • TB-500 — 10 mg
  • KPV — 10 mg

The four components represent distinct areas of peptide research, including extracellular matrix biology, cellular migration, tissue remodeling, inflammatory signaling, cytoskeletal dynamics, and cellular recovery pathways.

The scientific rationale for KLOW is based primarily on the complementary biological characteristics of its individual components. Research on the complete four-peptide combination remains limited compared with the substantially larger body of component-level research.


MECHANISM OF ACTION

KLOW Blend does not operate through a single defined molecular target. Instead, its research rationale involves several complementary biological pathways associated with its individual peptide components.

GHK-Cu

GHK-Cu is a copper-binding tripeptide complex associated with extracellular matrix remodeling, fibroblast biology, collagen-related processes, tissue repair signaling, and cellular responses involved in skin and connective-tissue biology.

BPC-157

BPC-157 is a synthetic pentadecapeptide investigated in preclinical research involving cellular signaling, vascular biology, nitric oxide pathways, angiogenic processes, and tissue-response mechanisms.

TB-500

TB-500 is associated with thymosin beta-4-related biology and research into actin dynamics, cytoskeletal organization, cellular migration, angiogenesis, and tissue remodeling.

KPV

KPV is a tripeptide derived from the C-terminal region of α-melanocyte-stimulating hormone (α-MSH). Research has investigated KPV in inflammatory signaling, melanocortin-related pathways, epithelial biology, and immune-cell responses.

Together, these components provide a multi-pathway research framework involving extracellular matrix regulation, cellular migration, inflammatory signaling, vascular biology, and tissue remodeling.


KEY BENEFITS

From a research perspective, the KLOW formulation provides:

  • Four complementary peptide research compounds in a single formulation
  • GHK-Cu-centered extracellular matrix and connective-tissue research
  • BPC-157-related cellular and vascular research pathways
  • TB-500-related cytoskeletal and cellular migration research
  • KPV-related inflammatory and melanocortin-pathway research
  • Multi-pathway investigation of tissue remodeling
  • Research into cellular migration and extracellular matrix biology
  • A standardized combined research formulation
  • A convenient platform for investigating interactions between distinct peptide pathways

RESEARCH AREAS

KLOW Blend may be investigated across several areas of experimental peptide research, including:

  • Tissue remodeling
  • Extracellular matrix biology
  • Fibroblast research
  • Collagen and connective-tissue biology
  • Cellular migration
  • Angiogenesis
  • Inflammatory signaling
  • Cytoskeletal dynamics
  • Wound-healing research
  • Vascular biology
  • Skin biology
  • Epithelial biology
  • Cellular stress responses
  • Regenerative biology
  • Peptide signaling research

The majority of available evidence concerns the individual components rather than the complete KLOW formulation.


SCIENTIFIC EVIDENCE

GHK-Cu

GHK-Cu has been extensively investigated as a copper-peptide complex in experimental research involving extracellular matrix organization, fibroblast activity, collagen-related processes, skin biology, angiogenesis, and tissue remodeling.

Its biological activity is associated with copper-dependent peptide interactions and modulation of cellular processes involved in matrix homeostasis.

BPC-157

BPC-157 has been studied primarily in preclinical models examining vascular signaling, cellular migration, tissue responses, nitric oxide pathways, and mechanisms associated with tissue recovery.

The existing literature is predominantly experimental, with substantially less evidence available from controlled human studies.

TB-500 / Thymosin Beta-4-Related Research

Thymosin beta-4 is a naturally occurring actin-binding peptide involved in cytoskeletal organization and cellular migration. Research has investigated thymosin beta-4-related mechanisms in angiogenesis, wound biology, tissue remodeling, and cellular movement.

The designation TB-500 is used commercially for research preparations associated with thymosin beta-4 biology, and the exact molecular composition of individual products should be evaluated from product-specific documentation.

KPV

KPV has been investigated as a small melanocortin-derived peptide with potential relevance to inflammatory signaling and epithelial/immune biology. Experimental research has examined interactions with inflammatory pathways and cellular responses.

Combined Formulation

The four components provide a mechanistically diverse research platform. However, the biological effects of the complete KLOW formulation cannot be assumed simply by combining evidence from the individual peptides. Controlled studies specifically evaluating the fixed four-component blend remain limited.


MOLECULAR PROFILE

Component Classification Amount
GHK-Cu Copper-binding tripeptide complex 50 mg
BPC-157 Synthetic pentadecapeptide 10 mg
TB-500 Thymosin beta-4-related peptide research material 10 mg
KPV α-MSH-derived tripeptide 10 mg
Total Multi-peptide formulation 80 mg

Individual Molecular Characteristics

Parameter GHK-Cu BPC-157 TB-500 KPV
Peptide Type Tripeptide + Cu(II) Pentadecapeptide Thymosin beta-4-related Tripeptide
Amino Acid Length 3 aa 15 aa 43 aa* 3 aa
Primary Research Domain ECM / connective tissue Cellular & vascular biology Cytoskeletal biology Inflammatory signaling
Approx. Molecular Weight ~402.9 Da ~1,419.5 Da ~4.96 kDa* ~342.4 Da

*Molecular characteristics depend on the specific TB-500 material and molecular definition used by the manufacturer.


PHARMACOKINETIC & PHARMACODYNAMIC PROFILE

Pharmacokinetic Profile

A definitive pharmacokinetic profile for the complete KLOW Blend has not been established.

Each component possesses distinct molecular characteristics, stability profiles, distribution properties, and biological kinetics. Consequently, the pharmacokinetic behavior of the complete formulation cannot be accurately represented by a single half-life or exposure parameter.

Available pharmacokinetic information is primarily component-specific and largely derived from experimental models.

Pharmacodynamic Profile

KLOW does not have a single established pharmacodynamic mechanism.

Its research profile encompasses multiple biological domains:

  • Extracellular matrix regulation
  • Fibroblast-associated signaling
  • Cellular migration
  • Actin and cytoskeletal dynamics
  • Vascular signaling
  • Angiogenic pathways
  • Inflammatory signaling
  • Melanocortin-related pathways
  • Tissue remodeling

The interaction between these pathways within the complete four-peptide formulation remains an area for further investigation.


RESEARCH HIGHLIGHTS

Multi-Pathway Peptide Platform

KLOW combines four peptides with distinct but potentially complementary research mechanisms within a single formulation.

Extracellular Matrix Research

GHK-Cu provides a major research component for investigations involving collagen, fibroblasts, extracellular matrix organization, and connective-tissue biology.

Cellular Migration & Vascular Biology

BPC-157 and TB-500-related research provides additional pathways for investigating cellular migration, vascular responses, and tissue remodeling.

Inflammatory Signaling

KPV expands the research scope of the formulation toward inflammatory and melanocortin-related cellular pathways.

Integrated Research Model

The combination enables researchers to investigate multiple biological pathways simultaneously rather than studying each peptide independently.

Analytical Characterization

The individual components can be evaluated through analytical techniques such as HPLC and mass spectrometry, supporting molecular identity and purity characterization at the lot level.


TECHNICAL SPECIFICATIONS

Parameter PharmaTech Specification
Product KLOW Blend
Total Peptide Content 80 mg
GHK-Cu 50 mg
BPC-157 10 mg
TB-500 10 mg
KPV 10 mg
Formulation Multi-peptide blend
Physical Form Lyophilized material
Appearance Lyophilized powder
Analytical Testing HPLC / MS, according to lot documentation
Lot Documentation Certificate of Analysis (COA)
Identity Testing Lot-specific
Purity Testing Lot-specific
Packaging PharmaTech research-grade vial
Batch Number PharmaTech lot-specific
Storage According to product label and lot documentation

STORAGE & HANDLING

Store KLOW Blend according to the temperature and handling specifications indicated on the PharmaTech product label and applicable lot documentation.

The lyophilized material should remain protected from excessive heat, moisture, light, and unnecessary temperature fluctuations.

Maintain the integrity of the original container until required for the intended laboratory application.

For maximum product traceability, retain the original vial, lot number, product documentation, and corresponding Certificate of Analysis throughout the research lifecycle.